Award
National Institute on Aging PAR-18-877
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
Recipient
National Institute on Aging (NIA)
Award Amount
$1,353,297.00
Ceiling
$1,353,297.00
Awarded
May 25, 2026
Identifier
PAR-18-877
A NIH-funded Phase 2 clinical trial to test PhytoSERM's effectiveness in preventing menopause-related cognitive decline and brain metabolism issues, supporting women's health and Alzheimer's disease risk reduction.
Description
The project aims to evaluate the efficacy of PhytoSERM in preventing menopause-related decline in brain metabolism and cognition, with secondary and tertiary outcomes including cognitive function, vasomotor symptoms, sleep quality, mood, and MRI biomarkers. It addresses multiple strategic directions of the National Institutes on Aging’s 2020-2025 plan, including developing interventions to maintain health and prevent age-related diseases, translating basic discovery into treatments, and supporting women’s health research. The project is funded under the full FOA PAR-18-877 and is part of a multi-year effort to address Alzheimer’s disease risk in women.